SPOTLIGHT: Prostate therapy achieves goal

AEterna Zentaris and Spectrum Pharmaceuticals announced that their experimental therapy for non-cancerous enlarged prostate improved symptoms in patients. After 12 weeks of dosing with Ozarelix, patients achieved a 47 percent higher evaluation score than patients taking a placebo. A late-stage trial is being planned. AEtner licensed Ozarelix back in 2004 for North America and India. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.